ReviewMucosal immunology2011
Macrophages and control of granulomatous inflammation in tuberculosis.
Review in Mucosal immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 230 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
230 citing papers in PubMed, 4 syntheses or guidelines pooled it, 414 citations in OpenAlex.
- Pooled it
- A meta-analysis of Th1 and Th2 cytokine profiles differentiating tuberculous from malignant pleural effusion.Scientific reports · 2022Pooled it
- Pathology of TB/COVID-19 Co-Infection: The phantom menace.Tuberculosis (Edinburgh, Scotland) · 2021Pooled it
- Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs.British medical bulletin · 2016Pooled it
- Adaptive Immunity in Marsupials.Journal of experimental zoology. Part A, Ecological and integrative physiology · 2026Review
- Mycobacterium tuberculosis infects human peripheral hematopoietic multipotent progenitors and promotes their myeloid differentiation in vitro.Cell death & disease · 2026Article
- Cefpiramide RestrictsACS medicinal chemistry letters · 2026Article
- Decoding PANoptosis: Crosstalk of cell death pathways in immunity and inflammation.Immunologic research · 2026Review
- YY1-activated LINC00926 promotes the survival of mycobacteria and regulates inflammatory response in Mycobacterium tuberculosis-infected macrophages.Archives of microbiology · 2026Article
- Interstitial and recruited macrophages prevent tuberculosis relapse by limiting immune evasion.EMBO molecular medicine · 2026Article
- Mycobacterium tuberculosis preferentially infects specific macrophage subsets in primate granulomas during the early stages of tuberculosis.Mucosal immunology · 2026Article
- Paradoxical hypercalcemia in tuberculosis with concurrent vitamin D deficiency: mechanisms, clinical implications, and management strategies.Annals of medicine and surgery (2012) · 2026Review
- A single mycobacterial ligand organizes multi-receptor signaling to reprogram macrophage lipid metabolism.bioRxiv : the preprint server for biology · 2026Article
- Multidrug-resistant tuberculosis: a comprehensive review of pathogenesis, drug resistance, current treatment and future prospects.Archives of microbiology · 2026Review
- Alternatively activated monocyte-derived myeloid cells promote extracellular pathogen persistence in pulmonary fungal granulomas.The Journal of experimental medicine · 2026Article
- Time Course Characterization of Protective Immune Responses Following BCG Vaccination in BALB/c Mice.Pathogens (Basel, Switzerland) · 2026Article
- CD8Nature communications · 2026Article
- Post-TB lung disease: pathogenesis, host-directed therapies, and the C3HeB/FeJ model for pre-clinical advances.Infection and immunity · 2026Review
- Molecular signaling in coinfection: howFrontiers in immunology · 2026Review
- Essential redundancies fuel Mycobacterium tuberculosis adaptation to the host.PLoS pathogens · 2025Review
170 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The granuloma that forms in response to Mycobacterium tuberculosis must be carefully balanced in terms of immune responses to provide sufficient immune cell activation to inhibit the growth of the bacilli, yet modulate the inflammation to prevent pathology. There are likely many scenarios by which this balance can be reached, given the complexity of the immune responses induced by M. tuberculosis. In this review, we focus on the key role of the macrophage in balancing inflammation in the granuloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.